Request To Download Free Sample of This Strategic Report @- The Global Xerostomia Therapeutics Market is poised for significant growth, with an anticipated reach of over USD 822.14 million by 2026, ...

Xerostomia associated with SS has to be differentiated from dry mouth produced by the intake of xerogenic drugs and the sequelae of radiotherapy and, in some cases, chemotherapy. [3,4,5,6 ...

Caring for elderly patients in the dental office can be challenging, but also extremely gratifying. It is a wonderful feeling ...

Ribox Therapeutics Ltd. has obtained IND clearance from the FDA for the company’s circular RNA therapy, RXRG-001.